Background: Deep learning models have gained significant traction in predicting drugtarget binding affinity, primarily focusing on deciphering intricate drug-target relationships. However, these models often overlook intermediate representations, thus failing to capture the holistic characteristics of proteins crucial for discerning drug-target interactions. Methods: This study proposes a novel deep-learning model that captures comprehensive and longrange dependencies within protein sequences. Leveraging deep feature engineering and an inverted Transformer module, it integrates multi-scale chemical information of drug molecules using graph neural networks and hierarchical attention mechanisms. Results: The proposed model achieves state-of-the-art performance across multiple drug-target interaction datasets. It obtains MSE losses of 0.229 and 0.162 on the Davis and KIBA datasets, respectively, and AUC scores of 0.982 and 0.985 on the Human and C. elegans datasets. Conclusion: These results demonstrate the model's superior efficacy in predicting drug-target affinity and interactions, showcasing its potential to expedite drug discovery processes.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: